Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
601 questions in 75 reviews · Schizophrenia
current versionsNo studies 601 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
ZUCLOPENTHIXOL DECANOATE vs PLACEBO Other adverse effects, general and specific · people with schizophrenia Zuclopenthixol versus placebo for schizophrenia (2015) · Cochrane | no estimate extracted | NR | No studies |
ZUCLOPENTHIXOL DECANOATE vs PLACEBO Leaving the study early · people with schizophrenia Zuclopenthixol versus placebo for schizophrenia (2015) · Cochrane | no estimate extracted | NR | No studies |
ZUCLOPENTHIXOL DIHYDROCHLORIDE vs PLACEBO Relapse as defined by the studies · people with with schizophrenia Zuclopenthixol versus placebo for schizophrenia (2015) · Cochrane | no estimate extracted | NR | No studies |
ZUCLOPENTHIXOL DECANOATE vs PLACEBO Average change in quality of life/satisfaction · people with schizophrenia Zuclopenthixol versus placebo for schizophrenia (2015) · Cochrane | no estimate extracted | NR | No studies |
ZUCLOPENTHIXOL DECANOATE vs PLACEBO Significant change in quality of life/satisfaction ‐ as defined by each of the studies · people with schizophrenia Zuclopenthixol versus placebo for schizophrenia (2015) · Cochrane | no estimate extracted | NR | No studies |
ZUCLOPENTHIXOL DIHYDROCHLORIDE vs PLACEBO Clinically significant response on psychotic symptoms ‐ as defined by each of the studies. · people with with schizophrenia Zuclopenthixol versus placebo for schizophrenia (2015) · Cochrane | no estimate extracted | NR | No studies |
ZUCLOPENTHIXOL DIHYDROCHLORIDE vs PLACEBO Average change in quality of life/satisfaction · people with with schizophrenia Zuclopenthixol versus placebo for schizophrenia (2015) · Cochrane | no estimate extracted | NR | No studies |
ZUCLOPENTHIXOL DIHYDROCHLORIDE vs PLACEBO Significant change in quality of life/satisfaction ‐ as defined by each of the studies · people with with schizophrenia Zuclopenthixol versus placebo for schizophrenia (2015) · Cochrane | no estimate extracted | NR | No studies |
ZUCLOPENTHIXOL ACETATE vs PLACEBO Clinically significant response on global state · people with schizophrenia Zuclopenthixol versus placebo for schizophrenia (2015) · Cochrane | no estimate extracted | NR | No studies |
ZUCLOPENTHIXOL ACETATE vs PLACEBO Relapse as defined by the studies · people with schizophrenia Zuclopenthixol versus placebo for schizophrenia (2015) · Cochrane | no estimate extracted | NR | No studies |
ASENAPINE vs PLACEBO Adverse effects: Clinically significant extrapyramidal symptoms AIMS · adults with schizophrenia Asenapine versus placebo for schizophrenia (2015) · Cochrane | no estimate extracted | NR | No studies |
ASENAPINE vs PLACEBO Economic costs · adults with schizophrenia Asenapine versus placebo for schizophrenia (2015) · Cochrane | no estimate extracted | NR | No studies |
CHLORPROMAZINE vs PLACEBO Satisfaction with treatment ‐ not reported · patients with schizophrenia Chlorpromazine versus placebo for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CHLORPROMAZINE vs PLACEBO Cost of care ‐ not reported · patients with schizophrenia Chlorpromazine versus placebo for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
FLUPENTHIXOL DECANOATE vs ORAL ANTIPSYCHOTICS Clinical response: mental state ‐ relapse ‐ medium term ‐ not reported · patients with schizophrenia or other similar psychotic disorders Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders (2014) · Cochrane | no estimate extracted | NR | No studies |
FLUPENTHIXOL DECANOATE vs OTHER DEPOT ANTIPSYCHOTICS Service utilisation: hospital admission ‐ medium/long term ‐ not reported · patients with schizophrenia or other similar psychotic disorders Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders (2014) · Cochrane | no estimate extracted | NR | No studies |
FLUPENTHIXOL DECANOATE vs OTHER DEPOT ANTIPSYCHOTICS Economic outcomes ‐ long term ‐ not reported · patients with schizophrenia or other similar psychotic disorders Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders (2014) · Cochrane | no estimate extracted | NR | No studies |
FLUPENTHIXOL DECANOATE HIGH DOSE vs FLUPENTHIXOL DECANOATE STANDARD DOSE (˜40 mg/IM) Clinical response: global state ‐ no clinical improvement ‐ short/medium term ‐ not reported · patients with schizophrenia or other similar psychotic disorders Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders (2014) · Cochrane | no estimate extracted | NR | No studies |
FLUPENTHIXOL DECANOATE HIGH DOSE vs FLUPENTHIXOL DECANOATE STANDARD DOSE (˜40 mg/IM) Service utilisation: hospital admission ‐ medium/long term ‐ not reported · patients with schizophrenia or other similar psychotic disorders Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders (2014) · Cochrane | no estimate extracted | NR | No studies |
FLUPENTHIXOL DECANOATE vs ORAL ANTIPSYCHOTICS Clinical response: mental state ‐ general score ‐ medium term ‐ not reported · patients with schizophrenia or other similar psychotic disorders Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders (2014) · Cochrane | no estimate extracted | NR | No studies |
FLUPENTHIXOL DECANOATE HIGH DOSE vs FLUPENTHIXOL DECANOATE STANDARD DOSE (˜40 mg/IM) Economic outcomes ‐ long term ‐ not reported · patients with schizophrenia or other similar psychotic disorders Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders (2014) · Cochrane | no estimate extracted | NR | No studies |
FLUPENTHIXOL DECANOATE VERY LOW (˜6 mg/IM) DOSE vs FLUPENTHIXOL DECANOATE LOW DOSE (˜9 mg/IM) Clinical response: mental state ‐ general score (BPRS) ‐ skew ‐ not reported · patients with schizophrenia or other similar psychotic disorders Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders (2014) · Cochrane | no estimate extracted | NR | No studies |
FLUPENTHIXOL DECANOATE VERY LOW (˜6 mg/IM) DOSE vs FLUPENTHIXOL DECANOATE LOW DOSE (˜9 mg/IM) Clinical response: global state ‐ no clinical improvement ‐ short/medium term ‐ not reported · patients with schizophrenia or other similar psychotic disorders Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders (2014) · Cochrane | no estimate extracted | NR | No studies |
FLUPENTHIXOL DECANOATE VERY LOW (˜6 mg/IM) DOSE vs FLUPENTHIXOL DECANOATE LOW DOSE (˜9 mg/IM) Service utilisation: hospital admission ‐ medium/long term ‐ not reported · patients with schizophrenia or other similar psychotic disorders Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders (2014) · Cochrane | no estimate extracted | NR | No studies |
FLUPENTHIXOL DECANOATE VERY LOW (˜6 mg/IM) DOSE vs FLUPENTHIXOL DECANOATE LOW DOSE (˜9 mg/IM) Leaving the study early ‐ medium/long term ‐ not reported · patients with schizophrenia or other similar psychotic disorders Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders (2014) · Cochrane | no estimate extracted | NR | No studies |
FLUPENTHIXOL DECANOATE VERY LOW (˜6 mg/IM) DOSE vs FLUPENTHIXOL DECANOATE LOW DOSE (˜9 mg/IM) Adverse effects: general ‐ movement disorders ‐ requiring anticholinergic medication ‐ short/medium term ‐ not reported · patients with schizophrenia or other similar psychotic disorders Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders (2014) · Cochrane | no estimate extracted | NR | No studies |
FLUPENTHIXOL DECANOATE VERY LOW (˜6 mg/IM) DOSE vs FLUPENTHIXOL DECANOATE LOW DOSE (˜9 mg/IM) Economic outcomes ‐ long term ‐ not reported · patients with schizophrenia or other similar psychotic disorders Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders (2014) · Cochrane | no estimate extracted | NR | No studies |
FLUPENTHIXOL DECANOATE vs ORAL ANTIPSYCHOTICS Clinical response: global state ‐ no clinical improvement ‐ medium term ‐ not reported · patients with schizophrenia or other similar psychotic disorders Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders (2014) · Cochrane | no estimate extracted | NR | No studies |
FLUPENTHIXOL DECANOATE vs ORAL ANTIPSYCHOTICS Service utilisation: hospital admission ‐ medium/long term ‐ not reported · patients with schizophrenia or other similar psychotic disorders Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders (2014) · Cochrane | no estimate extracted | NR | No studies |
FLUPENTHIXOL DECANOATE vs ORAL ANTIPSYCHOTICS Economic outcomes ‐ long term ‐ not reported · patients with schizophrenia or other similar psychotic disorders Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders (2014) · Cochrane | no estimate extracted | NR | No studies |
Perazine vs other antipsychotics Satisfaction with care ‐ not reported · patients with schizophrenia Perazine for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
Perazine vs other antipsychotics Quality of life ‐ not reported · patients with schizophrenia Perazine for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
Perazine vs placebo Satisfaction with care ‐ not reported · patients with schizophrenia Perazine for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
Perazine vs placebo Quality of life ‐ not reported · patients with schizophrenia Perazine for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY ABOUT CANNABIS AND PSYCHOSIS) vs NON‐SPECIFIC PSYCOEDUCTION Global state: relapse ‐ medium term ‐ not reported · patients with SCHIZOPHRENIA AND CANNABIS USE Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY ABOUT CANNABIS AND PSYCHOSIS) vs NON‐SPECIFIC PSYCOEDUCTION General functioning: no clinically important change in general functioning ‐ medium term ‐ not reported · patients with SCHIZOPHRENIA AND CANNABIS USE Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY ABOUT CANNABIS AND PSYCHOSIS) vs NON‐SPECIFIC PSYCOEDUCTION Adverse effects: no clinically important adverse effects ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA AND CANNABIS USE Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY ABOUT CANNABIS AND PSYCHOSIS) vs NON‐SPECIFIC PSYCOEDUCTION Leaving the study early ‐ medium term ‐ not reported · patients with SCHIZOPHRENIA AND CANNABIS USE Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY ABOUT CANNABIS AND PSYCHOSIS) vs NON‐SPECIFIC PSYCOEDUCTION Satisfaction with treatment ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA AND CANNABIS USE Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABIS REDUCTION: ANTIPSYCHOTIC 'A' vs ANTIPSYCHOTIC 'B' for Global state: relapse ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA. Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABIS REDUCTION: ANTIPSYCHOTIC 'A' vs ANTIPSYCHOTIC 'B' for General functioning: no clinically important change in general functioning ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA. Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABIS REDUCTION: ANTIPSYCHOTIC 'A' vs ANTIPSYCHOTIC 'B' for Satisfaction with treatment ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA. Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABINOID AS TREATMENT: CANNABIDIOL vs AMISULPRIDE Behaviour: Cannabis use: 1. frequency of use (group‐based therapy) (high = bad) ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABINOID AS TREATMENT: CANNABIDIOL vs AMISULPRIDE Mental state: PANSS total (high = bad) ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABINOID AS TREATMENT: CANNABIDIOL vs AMISULPRIDE Global state: relapse ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABINOID AS TREATMENT: CANNABIDIOL vs AMISULPRIDE General functioning: no clinically important change in general functioning ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABINOID AS TREATMENT: CANNABIDIOL vs AMISULPRIDE Adverse effects: measured adverse events ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABINOID AS TREATMENT: CANNABIDIOL vs AMISULPRIDE Leaving the study early: any reason ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABINOID AS TREATMENT: CANNABIDIOL vs AMISULPRIDE Satisfaction with treatment ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY vs TREATMENT Global state: relapse ‐ medium term ‐ not reported · patients with SCHIZOPHRENIA AND CANNABIS USE Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |